BIBR 1087 SE is an intermediate metabolite of dabigatran etexilate.

BIBR 1532 is a potent, selective, non-competitive telomerase inhibitor with IC50 of 100 nM.

BIBR 953 (Dabigatran, Pradaxa) is a highly selective, reversible, and potent thrombin inhibitor and is orally available as the prodrug, dabigatran etexilate.

BIBR-1048 (Dabigatran) is an anticoagulant from the class of the direct thrombin inhibitors.

BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.

BIBU1361 is a potent, selective, orally active EGFR inhibitor with IC50 of 3 nM, shows weak activity against HER2 (IC50=280 nM) and no inhibition on IGF1R, HGFR, Src, and VEGFR2 (IC50>10 uM).

BIBU1361 is a potent, selective, orally active EGFR inhibitor with IC50 of 3 nM, shows weak activity against HER2 (IC50=280 nM) and no inhibition on IGF1R, HGFR, Src, and VEGFR2 (IC50>10 uM).

BIBW2992 (Afatinib, Tomtovok, Tovok) irreversibly inhibits EGFR/HER2 including EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively.

Bictegravir is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.

Bicyclomycin benzoate is an antibiotic exhibiting activity against a broad spectrum of Gram-negative bacteria and against the Gram-positive bacterium.

BI-D1870 is a small molecule, specific inhibitor of p90 RSK (ribosomal S6 kinase) isoforms RSK1, RSK2, RSK3 and RSK4, both in vitro and in vivo, with IC50s are 31 nM, 24 nM, 18 nM, 15 nM, respectively.

BIIB021(CNF2024) is an orally available, fully synthetic small-molecule inhibitor of HSP90 with Ki and EC50 of 1.7 nM and 38 nM, respectively.

BIIL260 is the active metabolite of BIIL284, shows high affinity to LTB4 receptor on isolated human neutrophil cell membranes with Ki of 1.7 nM.

Bikinin is a strong activator of brassinosteroid (BR) signaling.

Bilastine is a selective histamine H1 receptor antagonist used for treatment of allergic rhinoconjunctivitis and urticaria.

BILH-434 is a potent HPV11 E1/E2/DNA complex inhibitor that binds to the transactivation domain (TAD) of E2 protein with a Kd of 40 nM, has an IC50 of 180 nM in the E1-E2-ori complex formation assay..

Bilobalide is a sesquiterpene lactone which is found in extracts of G. biloba.

Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.

Bindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.

BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5, also a pan-JAKinhibitor.

BIO 8898 is a synthetic, CD40-CD154 co-stimulatory interaction inhibitor that inhibits the TNF family cytokine CD40L binding to CD40-Ig with a potency of IC50=25 uM.

BIO1211 (BIO-1211) is a potent, highly specific integrin α4β1 (VLA-4) inhibitor with Kd/IC50 of 20 pM/4 nM for the activated form of α4β1.

BIO124 (BIO-124) is a modest inhibitor of the PICK1-GluA2 interaction with IC50 of 0.51 uM in FP assays, binds to the PDZ domain of PICK1..

BIO922 (BIO 922, BIO-922) is a small molecule PICK1 inhibitor that specificly blocks the PDZ domain-mediated interaction between GluA2 and PICK1 (IC50=69 nM), blocks the effects of Aβ on synaptic transmission and surface receptors.

BIO-Acetoxime is an analog of the GSK3 inhibitor 6-bromoindirubin-3’-oxime, or BIO

Bio-AMS is a chemical inhibitor of Mycobacterium tuberculosis biotin protein ligase ( MtBPL) with Kd of 0.865 nM.

Bioymifi(DR5 Activator) is the first novel and potent small-molecule activatior of the TRAIL receptor DR5 in human cancer cells.

Biperiden (KL 373) is a centrally-acting antiparkinsonian agent that functions as a selective central M1 cholinoreceptors blocker..

Biperiden Hcl (NSC 170950, NSC 84989) is a centrally-acting antiparkinsonian agent that functions as a selective central M1 cholinoreceptors blocker..

BIRB 796 (Doramapimod) is a highly selective p38α MAPK inhibitor with Kd of 0.1 nM, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2, ZAP-70, EGFR, HER2, PKA, PKC, PKCα/β/γ.

Birinapant (TL32711) is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM, less potent to XIAP.

Bis(tributylammonium) difluoromethylenediphosphonate

Bisantrene is a highly effective antitumor drug, targets eukaryotic type II topoisomerases.

BISF CAS 118511-97-0

Bisindolylmaleimide X is a cell-permeable, reversible, ATP-competitive protein kinase C (PKC) inhibitor (IC50 = 15 nM, rat brain PKC).

Bisindolylmaleimide X is a cell-permeable, reversible, ATP-competitive protein kinase C (PKC) inhibitor (IC50 = 15 nM, rat brain PKC).

Bisperoxovanadium (bpV(phen) potassium hydrate) is a bisperoxovanadium (bpV) compound which inhibits several different protein tyrosine phosphatases (PTPs), with selectivity for PTEN (IC50 =38 nM), also inhibits the vascular endothelial PTP, PTP-β (IC50=3

Bisphenol A is a starting material for the synthesis of plastics, primarily certain polycarbonates and epoxy resins, as well as some polysulfones and certain niche materials. It exhibits estrogen-mimicking, hormone-like properties.

Bis-T-23 is a small molecule that stimulates actin-dependent dynamin oligomerization and promotes dynamin GTPase activity, increases actin polymerization in injured podocytes.

Bitertanol is a broad-spectrum triazole fungicide that is active against a variety of fungi, including V. inaequalis and V. pirina.

Bitopertin, also known as RG1678, is a potent and selective inhibitor of GlyT1 with an EC50 of 30nM.

BIX 02565 is a novel ribosomal S6 kinase 2 (RSK2) inhibitor with an IC50 of 1.1 nM.

BIX01294 is an inhibitor of G9a histone methyltransferase with IC50 of 2.7 μM.

BIX02188 is a selective inhibitor of MEK5 with IC50 of 4.3 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.

BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.

Bizine is a phenelzine analog that inhibits LSD1 with Ki of 59 nM, displays 23-fold, 63-fold, and >100-fold selectivity for LSD-1 over MAOA, MAOB, and LSD2 respectively.

BJE6-106 (B106) is a potent, selective PKCδ inhibitor with IC50 of 50 nM, displays excellent selectivity over classical PKC isozymes (a 1,000-fold PKCδ selectivity over PKCα).

BKI-1369 is a bumped kinase inhibitor (BKI). BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, stability, metabolism, toxicity, pharmacokinetics and is potent against C. parvum in infected mice and calves.

BKM120 is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ.

BL-1020 is an ester of GABA and perphenazine, fuctions as orally-active antipsychotic agent and acts as a D2 antagonist and GABA agonist.

BL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively.

BL-918 is a small molecule activator of ULK1 with EC50 of 24 nM (243% kinase activity at 100 nM), induces autophagy via the ULK complex in SH-SY5Y cells.

BL-AD008 (BL-AD 008) is a novel small molecule, dual-target activator targeting AMPK/ZIPK; demonstrates remarkable anti-proliferative activities toward cervical cancer cells and could induce apoptosis by death-receptor and mitochondrial pathways; also sho

Blasticidin S hydrochloride is a nucleoside antibiotic isolated from Streptomyces griseochromogenes. Blasticidin S is a potent inhibitor of protein synthesis in both prokaryotic and eukaryotic cells.

Bleomycin sulfate (Blenoxane) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Blonanserin(AD-5423) is a D2/5-HT2 receptor antagonist, atypical antipsychotic.

BLT-1 is an irreversible Scavenger receptor class B member I (SR-BI) inhibitor that blocks SR-BI-mediated selective lipid uptake and bidirectional cholesterol flux with an IC50 of 50 nM; significantly inhibits baicalin-induced cholesterol efflux in THP-1 macrophages.

BLU-285 is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V.

BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor.

BLU-667 (Pralsetinib) is a highly potent, selective, next generation RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion.

BLU-667 trans form is the trans form of BLU-667, which is a highly potent, selective, next generation RET inhibitor..

BLU-782 (BLU782) is a novel potent, selective inhibitor of Activin receptor-like kinase (ALK2) mutant R206H with binding IC50 of <10 Nm.

BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM).

BLZ945 is a highly selective and brain-penetrant inhibitor of CSF1R with IC50 of 1 nM; >3200-fold higher than its affinity for other kinases.

BM-1197 is a potent, specific dual inhibitor of Bcl-2 and Bcl-xL with Ki of <1 nM, shows >1,000-fold selectivity over Mcl-1.

BM-212 is a potent antimycobacterial agent and MmpL3 inhibitor.

BM-635 is a small molecule anti-mycobacterial compound acting by inhibiting the mycobacterial membrane protein Large 3 (MmpL3).

BM-957 is a highly potent, dual Bcl-2 and Bcl-xL inhibitor with Ki of <1 nM for both, IC50 of 5.4 and 6.0 nM, respectively.

BMH-21 is a small molecule DNA intercalator that binds ribosomal DNA and inhibits RNA polymerase I transcription; does not cause phosphorylation of H2AX.

BML-190 is an indomethacin morpholinylamide which functions as a selective inverse agonist of the human cannabinoid CB2 receptor.

BML-210 is the novel HDAC inhibitor, and its mechanism of action has not been characterized.

BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.

AMBMP hydrochloride is a Wnt canonical signaling activator. Also inhibits tubulin polymerization. Suppresses TLR2/4/5-induced inflammatory response in human monocytes. Inhibits cell proliferation and induces cell cycle arrest in MDA-MB-231 breast cancer c

Bm-MPK1-IN-15b is a potent, orally bioavailable inhibitor of B. malayi stress-activated kinase Bm-MPK1 with IC50 of 24 nM.

Talazoparib, also known as BMN-673 and MDV-3800, is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity (PARP1 IC50 = 0.57 nmol/L). Talazoparib acts as an inhibitor of poly ADP ribose polymerase(PARP) which aids in single strand DNA repair. Cells that have BRCA1/2 mutations are susceptible to the cytotoxic effects of PARP inhibitors because of an accumulation of DNA damage. Talazoparib is theorized to have a higher potency than olaparib due to the additional mechanism of action called PARP trapping. PARP trapping is the mechanism of action where the PARP molecule is trapped on the DNA, which interferes with the cells ability to replicate. Talazoparib is found to be ~100 fold more efficient in PARP trapping than olaparib.

BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM.

BMN-673 (8R,9S) is the (8R,9S) enantiomer of BMN-673. BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM(PARP1). It does not inhibit PARG and is highly sensitive to PTEN mutation.

BMP signaling agonist sb4 is a small molecule BMP signaling agonist with EC50 of 73.6 nM, enhances the efficacy of BMPs and activates endogenous BMP4 target genes.

BMS 695735 is a potent, selective IGF-1R inhibitor with IC50 of 34 nM.

A novel potent, selective, orally active human 11β-HSD1 inhibitor with IC50 of 3.0 nM.

BMS-189453 (BMS189453, BMS453) is a synthetic retinoid that acts as an agonist of RARβ and an antagonist of RARα and RARγ.

BMS-2 is a potent MET kinase inhibitor with an IC50 value of 1.8nM. It also possesses potent inhibitory activity against Flt-3 and VEGFR-2 kinases, IC50 values of 4nM and 27nM respectively.

BMS-211 is a prodrug of the parent pan-CK2 inhibitor BMS-699..

BMS-212 is a potent and selective stimulator of glucokinase (GK) (EC50 = 35 nM) that is promisingly used as an antidiabetic.

BMS-214662 is a potent and selective farnesyl transferase inhibitor with potent antitumor activity with an IC50 of 1.35 nM.

BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.

BMS-3 is a potent inhibitor of the LIM kinase. It has IC50's of 5nM and 6 nM for LIMK1 and LIMK2 respectively.

BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor with IC50 value of 0.13 uM (human recombinant ACL).

BMS309403 is orally active, reducing atherosclerosis in mice lacking apoplipoprotein E.

BMS-394136 is a potent, selective IKur/Kv1.5inhibitor, increases atrial action potential duration (APD) and prolongs AERP but not VERP in both rabbits and beagles..

BMS433771 is a potent, orally active RSV fusion inhibitor, exhibits excellent potency against multiple laboratory and clinical isolates of both group A and B viruses with mean EC50 of 20 nM.

BMS-457 is a potent and selective CCR1 antagonist with binding IC50 of 0.8 nM, >1,000-fold selectivity against other CC family receptors.

BMS-536924 is an ATP-competitive IGF-1R inhibitor with IC50 of 100 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

BMS-538203 is a highly efficient HIV integrase inhibitor and antiviral agent.

BMS-564929 is a potent, selective androgen receptor modulator (SARM) that binds to AR with Ki of 2.11 nM.

BMS-582949 is a dual action p38 Kinase Inhibitor.

BMS-595 (BMS595) is a novel potent, selective, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 1.3 nM (CKα).

BMS-599626 (AC-480) is a potent, selective inhibitor of EGFR and HER2 with IC50 of 20 nM and 30 nM.

BMS-599626 (AC480) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, respectively.

BMS-626529 is a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T-cells.

BMS-641988 is a potent, selective, nonsteroidal androgen receptor antagonist with Ki of 1.7 nM, MDA-MB-453 cell IC50 of 16 nM.

BMS-654457 is a potent, reversible and direct inhibitor of factor XIa (FXa) with Ki of 0.4 nM.

BMS687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) α agonist, with an EC50 of 10 nM for human PPARα and ∼410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays.

BMS-699 (BMS699) is a novel potent, selective, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 0.1 nM (CKα).

BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity.

BMS-708163 is a potent, selective γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, respectively.

BMS-741672 is a potent, selective CCR2 antagonist for the treatment of neuropathic pain..

BMS-751324 is a novel clinical prodrug of BMS-582949, which is a highly selective p38α MAPK inhibitor with IC50 of 13 nM.

BMS-754807 is a potent and reversible inhibitor of IGF-1R/IR family kinases, inhibits IGF-1R, IR, Met, TrkA and TrkB with IC50 of 1.8 nM, 1.7 nM, 5.6 nM, 7.4 nM and 4.1 nM, respectively.

BMS-779788(XL652) is a novel small-molecule modulator of the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders.

BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7/15 nM; also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378.

BMS-795311 is a potent and orally available CETP inhibitor with IC50 of 3.8 nM, inhibits cholesteryl ester (CE) transfer with IC50 of 0.22 uM.

BMS-806 (BMS 378806) is a small molecule gp120/CD4 inhibitor with an IC50 of median 5 nM.

BMS-813160 is a dual CCR2/CCR5 chemokine antagonist.

BMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.

BMS-817399 is a potent, selective, orally bioavailable CCR1 antagonist with binding IC50 of 1 nM, inhibits MIP-1α-induced chemotaxis with IC50 of 6 nM.

BMS-818251 (BMS818251) is a novel potent, small-molecule inhibitor of HIV-1 entry with EC50 of 0.019 nM against e laboratory-adapted HIV-1 strain NL4-3.

BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2.

BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2.

BMS 833923 is an orally bioavailable inhibitor of Smo. It blocks binding of BODIPY cyclopamine (IC50 = 21 nM) and inhibits Gli activation in cell lines that express wild-type Smo or activated mutant forms of Smo (IC50s = 6-35 nM). BMS 833923 robustly inhi

BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.

BMS-869780 is a potent γ-secretase modulator (GSM) that decreases Aβ1-42 (IC50=5.1 nM) and Aβ1-40 (IC50=25.1 nM) and increases Aβ1-37 and Aβ1-38 without inhibiting overall levels of Aβ peptides or other APP processing intermediates.

BMS-871 is a potent, orally active pan-Notch inhibitor with IC50 of 4/1/4/3 nM for Notch1/2/3/4, respectively.

BMS-884775 is a potent, selective P2Y1 antagonist with IC50 of 0.12 nM.

BMS-901715 is a potent, selective adapter protein-2 associated kinase 1 (AAK1) inhibitor..

BMS-906024 is a highly potent, selective inhibitor of γ-secretase mediated signaling of Notch1/2/3/4 receptors with IC50 of 1.6/0.7/3.4/2.9 nM, respectively.

BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, approximately 350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively.

BMS-919373 is a potent I(Kur)/Kv1.5 channel blocker with IC50 of 50 nM, with selectivity versus hERG, Na, Ca channels and reduced the level of brain penetration.

BMS-932481 (BMS932481) is a potent, selective, orraly active γ-secretase modulator (GSM), shows selectivity for Aβ40 and Aβ42 reduction (IC50=6.6 nM) while sparing total Aβ levels both in vitro and in vivo.

BMS-933043 is a novel highly selective, potent α7 nAChR partial agonist with binding Ki of 3.3 and 8.1 nM for rat and human α7, respectively.

BMS-952048 is a positive allosteric modulator of mGluR5 with EC50 of 10 nM..

BMS-955176 (GSK-3532795) is a second-generation HIV-1 maturation inhibitor that exhibits potent activity (EC50=3.9±3.4 nM) against a library (n=87) of gag/pr recombinant viruses.

BMS-961955 is an potent, allosteric inhibitor of HCV NS5B polymerase with EC50 of 7.9/4.3 nM for GT 1b/1a replicon respectively.

BMS-962212 is a potent, highly selective and reversible small molecule coagulation Factor XIa (FXIa) inhibitor with Ki of 0.7 nM.

BMS-983970 (BMS983970) is a potent, orally active, pan-Notch inhibitor, demonstrates robust anti-tumor activity at tolerated doses in multiple tumor xenograft models..

BMS-984923 (BMS-984923) is a potent silent allosteric modulator (SAM) of mGluR5 with competitive antagonism of MPEPy binding with Ki of 0.6 nM, but has no detectable agonist and antagonist activity at mGluR5 signaling.

BMS-986020 is an LPA1 antagonist.

BMS-986115 is an orally bioavailable, γ-secretase and pan-Notch inhibitor with potential antineoplastic activity.

BMS-986118 is a potent and selective GPR40 agonist with EC50 of 70 and 63 nM for hGPR40 and mGPR40, shows no PPARγ activity (EC50>47 uM).

BMS-986120 (BMS986120) is a potent, selective, orally bioavailable, and reversible PAR4 antagonist with Kd of 0.098 nM for human PAR4.

BMS-986122 is a potent positive allosteric modulator of μ-opioid receptor, significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells..

BMS-986142 is a potent, selective, and reversible BTK (Bruton’s tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM).

BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins.

BMS-986163 is a water-soluble phosphate prodrug of BMS-986169, which is a novel GluN2B negative allosteric modulator (Ki=4.0 nM)..

BMS-986165 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2).

BMS-986166 (BMS986166) is a potent, selective S1P receptor modulator for the treatment of ulcerative colitis..

BMS-986169 is a novel GluN2B negative allosteric modulator, demonstrates high binding affinity for the GluN2B allosteric site (Ki=4.0 nM) and selective inhibition of GluN2B receptor function (IC50=24 nM) in cells.

BMS-986187 is a novel potent, positive allosteric modulator of δ-opioid receptor with EC50 of 30 nM, 100-fold selectivity over μ-opioid receptor..

BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK).

BMS-986202 is a clinical Tyk2 inhibitor that binds to Tyk2 JH2 with IC50 of 0.19 nM and shows remarkably selectivity over other kinases including Jak family members.

BMS-986205 is an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic activity, alone and in combination with nivolumab in advanced cancers in a phase 1/2a trial

BMT-046091 (BMT046091) is a potent and selective AAK1 inhibitor with IC50 of 2.8 nM.

BMT-090605 (BMT 090605, BMT090605) is a potent, selective adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC50 0.6 nM.

BMT-145027 is a potent mGluR5 PAM with no inherent mGluR5 agonist activity.

BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3.

BNC-1 is a small molecule modulator of Amyloid pathology by promoting phosphorylation and activation of Elk-1, a transcriptional repressor of presenilin-1 but not presenilin-2.

BNC105 is a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy.

BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.

BNS-22 is a small-molecule inhibitor of DNA topoisomerase II, inhibits kinetoplast DNA decatenation that is mediated by human TOP2α and TOP2β in vitro with IC50 of 2.8 and 0.42 uM, respectively.

Bobcat339 (Bobcat 339) is a novel cytosine-based TET enzyme inhibitor with IC50 of 33 uM (TET1) and 73 uM (TET2), but not DNMT3a, does not inhibit the DNA methyltransferase DNMT3a.

BOC-D-FMK is a cell-permeable, irreversible, broad spectrum caspase inhibitor, inhibits apoptosis stimulated by TNF-α with IC50 of 39 uM.

Boceprevir(EBP 520; SCH 503034 ) is useful for Anti HCV.

Boc-MLF (TFA) is a peptide, used as a specific formyl peptide receptor (FPR) antagonist, also inhibits the signaling through formyl peptide receptor like 1 (FPRL1) at higher concentrations.

Bohemine is a synthetic, cell-permeable, cyclin-dependent kinase inhibitor.

Boldenone undecylenate(Equipoise) is a synthetic steroid which has a similar effect as the natural steroid testosterone; it is frequently used in veterinary medicine, though it is also used in humans.

Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM.

Borussertib is a potent, first-in-class, covalent-allosteric AKT inhibitor.

BOS172722 (BOS-172722) is a potent, selective MPS1 kinase inhibitor with biochemical IC50 of 11 nM, 100-fold selectivity over CDK2.

Bosentan is a competitive and dual antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors.

Bosentan is an endothelin (ET) receptors antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.

Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity.

Box5 is a Wnt5a-derived N-butyloxycarbonyl hexapeptide (t-Boc-Met-Asp-Gly-Cys-Glu-Leu), acts as an Wnt5a antagonist.

BP-1-102 is a potent, orally bioavailable and selective STAT3 inhibitor.

BP897 is a partially selective D3 dopamine receptor agonist.

BPIPP is an inhibitor of GC-C (guanylyl cyclase type C) that inhibits stimulation of guanylyl cyclase and adenylyl cyclase, suppresses cGMP accumulation in a variety of cell lines (IC50=3.4-11.2 uM).

BPK-29 is a covalent, specific small molecule that disrupts NR0B1 protein complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells.

BPN14770 (BPN-14770) is an allosteric inhibitor of phosphodiesterase 4D (PDE4D) with IC50 of 7.8 and 7.4 nM for human PDE4D7 and PDE4D3 respectively, displays 16-fold less potent against monomeric form of PDE4D lacking the UCR1 dimerization domain (PDE4D2

BPN-15606 (BPN15606) is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 by SHSY5Y neuroblastoma cells with IC50 of 7 nM.

BPO-27 racemate is a potent CFTR inhibitor with an IC50 of 8 nM.

BPR1J-097 is a novel small molecule FLT-3 inhibitor(IC50=11±7 nM) with promising in vivo anti-tumour activities; inhibits FLT-3 D835Y with an IC50 of 3 nM.

BPR1J373 is a potent, orally available multitargeted kinase inhibitor, potently inhibits FLT3, c-KIT, VEGFR1-3, Aurora A, PDGFRα, PDGFRβ, RET, and SRC with IC50 values of <100 nM.

BPR1K653 is a novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively.

BPTES is a selective inhibitor of Glutaminase GLS1 (KGA)

BPTU is an Allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM).

BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.

BQ-788 sodium salt is a potent, selective ETB receptor antagonist (IC50 = 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells); poorly inhibited the binding to ET A receptors in human neuroblastoma cell line SK-N-MC cells (IC(50), 1300 nM).

BQCA is a potent muscarinic M1 receptor positive allosteric modulator with selectivity for M1 over M2-M5.

BQU-082 is a novel potent small GTPase Ral (Ras-like) inhibitor with IC50 of 1.7 uM, displays a dose dependent effect on RalA and RalB activity in H2122 spheroids using the common RalBP1 pull-down assay..

BQU57 is a potent and selective GTPase Ral Inhibitor.

BR101549 (BR-101549) is a novel PPARγ non-TZD agonist with EC50 of 1.73 uM (Amax 120%)..

BR103 is a potent, metabolically stable and highly selective small molecule agonist of complement C3a receptor (C3aR) with EC50 of 22 ± 8  nM.

BR111 is a potent, highly selective and orally active antagonist of complement C3a receptor (C3aR) with IC50 of 85 ± 40  nM (inhibition of hC3a induced Ca2+ release on human macrophages).

BR351 is a brain penetrant MMP inhibitor with IC50s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively. Potential tools for the molecular imaging of activated MMPs with PET.

BR351 precursor is a precursor of BR351. BR351 is a brain penetrant MMP inhibitor with IC50s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively. Potential tools for the molecular imaging of activated MMPs with PET.

BRACO-19 is a potent small molecule Telomerase inhibitor (IC50=115 nM) that inhibits expression of human telomerase reverse transcriptase (hTERT).

BRACO19 is a telomerase inhibitor that stabilizes G-quadruplexes, targeting telomeric G-quadruplexes, inducing DNA damage and cell-cycle arrest.

Bractoppin is a potent, small-molecule chemical inhibitor that specific selectively blocks phosphopeptide recognition by the BRCA1 tBRCT domain with binding IC50 of 74 nM; shows no inhibition for recognition of cognate biotinylated phosphopeptides to the TOPBP1 tBRCT 7/8, or GRB2 SH2 proteins; engages BRCA1 tBRCT residues recognizing pSer in the consensus motif, pSer-Pro-Thr-Phe, plus an abutting hydrophobic pocket; inhibits substrate recognition detected by Förster resonance energy transfer, and diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51; selectively interrupts BRCA1 tBRCT-dependent signals evoked by DNA damage.

Bradanicline (TC-5619) is an experimental pharmaceutical drugthat acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors.